Introduction
============

Diabetes mellitus remains a public health problem in Taiwan due to its high incidence and prevalence, and significant mortality ([@B16]; [@B8]; [@B36]). One epidemiological study using the database of Taiwan National Health Insurance Program has shown that the incidence and the prevalence of diabetes mellitus gradually increased in Taiwan from 2000 to 2008 ([@B9]). Overall, the increase of the incidence was 14.6% for women and 29.6% for men from 2000 to 2008 ([@B9]). The increase of the prevalence was 56% for women and 74% for men from 2000 to 2008 ([@B9]). Diabetes mellitus was the fifth leading cause of death in Taiwan in 2015 (crude mortality rate 40.6/per 100000 persons) ([@B27]). Diabetes mellitus has been associated with increased risk of some comorbidities including microvascular and macrovascular complications, and cancer ([@B4]; [@B29]; [@B31]; [@B6]). One meta-analysis has shown that diabetes mellitus is associated with increased risk of gallbladder disease including gallstones, cholecystectomy, and cholecystitis (relative risk 1.56, 95% CI: 1.26--1.93) ([@B3]).

Metformin is the first-line medication to treat diabetes mellitus. To date, no large scale study explores the association between gallstones and metformin use. Therefore, a population-based retrospective cohort study was conducted using the database of the Taiwan National Health Insurance Program to explore the association between gallstones and metformin use.

Materials and Methods {#s1}
=====================

Ethics Statement
----------------

The Institutional Review Board of Taichung Tzu Chi General Hospital in Taiwan approved the study protocol (REC104-30). Because the identification numbers and personal information of the individuals in the study were not included in the secondary files, the review board waived the need for written consent.

Data Source, Study Design, and Subject Selection
------------------------------------------------

Taiwan is an independent country with more than 23 million people ([@B13]; [@B17]; [@B18]; [@B19]; [@B20]; [@B23]; [@B24]; [@B25]; [@B32]; [@B33]; [@B34]; [@B35]; [@B38]; [@B39]; [@B11]; [@B15]). A population-based retrospective cohort study was conducted using the database from the Taiwan National Health Insurance Program. The database is available to researchers ([@B28]).

Subjects of newly diagnosed diabetes mellitus (International Classification of Diseases, Ninth Revision, Clinical Modification, ICD-9 code 250) were included from 2002 to 2013. The date for subjects being diagnosed with diabetes mellitus was defined as the index date. Subjects who had a diagnosis of gallstones, or had at least a prescription for metformin before the index date were excluded from the study.

Major Endpoint
--------------

It was a new diagnosis of gallstones during the follow-up period.

Comorbid Conditions and Socioeconomic Status
--------------------------------------------

Comorbid conditions and socioeconomic status were included as follows: atrial fibrillation, chronic kidney disease, coronary artery disease, heart failure, hypertension, lipid disorders, socioeconomic status, urbanization, and geographic region of residence. All comorbid conditions were diagnosed based on ICD-9 codes, which have been discussed in previous studies ([@B7]; [@B30]; [@B10]; [@B14]; [@B21],[@B22]).

Assessment of Metformin Exposure
--------------------------------

The definition of defined daily dose (DDD) was adapted from previous studies as follows ([@B26]; [@B37]; [@B12]). The DDD is regarded as a unit for estimating a prescribed amount of a medication. It is the assumed average daily maintenance dose of a medication prescribed for its major indication in adults. The cumulative DDD, which indicates the exposure duration of a medication, was estimated as the sum of dispensed DDD of metformin to compare its use with the risk of gallstones. The metformin-exposure group was defined as ≥29 cumulative DDD of metformin. The un-exposure group was defined as \<29 cumulative DDD of metformin.

Other anti-diabetic medications were included as follows: dipeptidyl peptidase-4 inhibitor, insulin, sulfonylurea, and thiazolidinedione.

Statistical Analysis
--------------------

SPSS version 19 (SPSS Inc., Chicago, IL, United States) was used for all data analyses. Pearson's chi-square test was used for categorical variables such as sex, other anti-diabetic medications use, comorbid conditions, socioeconomic status, urbanization, and geographic region of residence. Continuous variables were analyzed using one-way analysis of variance (ANOVA). A multivariable Cox proportional hazards regression model was used to evaluate the hazard ratio (HR) and 95% confidence interval (CI) of gallstones associated with metformin use after adjustment for subject characteristics (including age, sex, other anti-diabetic medications, comorbid conditions, socioeconomic status, urbanization, and geographic region of residence). Statistical significance was set at a two-sided *P* \< 0.05.

Results
=======

Characteristics of the Study Population
---------------------------------------

**Table [1](#T1){ref-type="table"}** reveals the baseline characteristics between the metformin-exposure group and the un-exposure group. The study included 10182 subjects in the metformin-exposure group and 10182 subjects in the un-exposure group, with similar distributions of age and sex. The proportions of other anti-diabetic medications use, hypertension, and lipid disorders were statistically higher in the metformin-exposure group than the un-exposure group (Pearson's chi-square test, *P* \< 0.05).

###### 

Baseline characteristics of the study population.

  Variable                                 Exposure to metformin   Un-exposure   *P*-value
  ---------------------------------------- ----------------------- ------------- -----------
  Subjects number                          10182                   10182         
  Mean age, years (±standard deviation)    55 ± 21                 55 ± 21       NA
  **Sex**                                                                        NA
  Male                                     5095 (50.0)             5095 (50.0)   
  Female                                   5087 (50.0)             5087 (50.0)   
  **Other anti-diabetic drugs**                                                  
  Dipeptidyl peptidase-4 inhibitor         2887 (28.4)             576 (5.7)     \<0.001
  Insulin                                  4252 (41.8)             2460 (24.2)   \<0.001
  Sulfonylurea                             8300 (81.5)             3809 (37.4)   \<0.001
  Thiazolidinedione                        2593 (25.5)             505 (5.0)     \<0.001
  **Comorbidities**                                                              
  Atrial fibrillation                      139 (1.4)               179 (1.8)     0.024
  Chronic kidney disease                   43 (0.4)                230 (2.3)     \<0.001
  Coronary artery disease                  903 (8.9)               977 (9.6)     0.073
  Heart failure                            329 (3.2)               363 (3.6)     0.189
  Hypertension                             3770 (37.0)             3375 (33.1)   \<0.001
  Lipid disorders                          1482 (14.6)             1348 (13.2)   0.007
  **Socioeconomic status**                                                       0.581
  Low socioeconomic status                 4425 (43.5)             4386 (43.1)   
  Moderate and high socioeconomic status   5757 (56.5)             5796 (56.9)   
  **Urbanization**                                                               0.128
  Urban                                    2839 (27.9)             2937 (28.8)   
  Un-urban                                 7343 (72.1)             7245 (71.2)   
  **Geographic region of residence**                                             0.063
  Northern/Central                         6643 (65.2)             6769 (66.5)   
  Southern/Eastern                         3539 (34.8)             3413 (33.5)   
                                                                                 

The metformin-exposure group was defined as ≥29 cumulative defined daily dose (cumulative DDD) of metformin use. The un-exposure group was defined as\<29 cumulative DDD of metformin use.

Association of Gallstones with Metformin Use
--------------------------------------------

After adjustment for subject characteristics (including age, sex, other anti-diabetic medications, comorbid conditions, socioeconomic status, urbanization, and geographic region of residence), a multivariable Cox proportional hazards regression model revealed that the adjusted HRs of gallstones were 1.11 (95%CI: 0.84--1.46) for subjects with metformin dosage of 29--180 cumulative DDD, and 0.57 (95%CI: 0.42--0.78) for subjects with metformin dosage \>180 cumulative DDD, compared with the un-exposure group (**Table [2](#T2){ref-type="table"}**).

###### 

Hazard ratio (HR) and 95% confidence interval (CI) of gallstones associated with metformin use in a multivariable Cox proportional hazard model.

  Metformin use                                Gallstones          
  -------------------------------------------- ------------------- ---------
  Un-exposure                                  (Reference)         
  Metformin dosage of 29--180 cumulative DDD   1.11 (0.84--1.46)   0.469
  Metformin dosage \>180 cumulative DDD        0.57 (0.42--0.78)   \<0.001
                                                                   

HR, hazard ratio; CI, confidence interval; Adjusted for age, sex, dipeptidyl peptidase-4 inhibitor, insulin, sulfonylurea, thiazolidinedione, atrial fibrillation, chronic kidney disease, coronary artery disease, heart failure, hypertension, lipid disorders, socioeconomic status, urbanization, and geographic region of residence.

Discussion
==========

We found that metformin use was associated with reduced risk of gallstones for subjects with metformin dosage \>180 cumulative DDD (adjusted HR 0.57, **Table [2](#T2){ref-type="table"}**). However, the HR was 1.11 for subjects with metformin dosage of 29--180 cumulative DDD, without statistic significance. These findings indicate that there is a duration-response relationship between the risk of gallstones and metformin use. That is, the protective effect on gallstones is greater for longer duration of metformin use.

The mechanisms underlying the protective effect of metformin use cannot be fully determined in our observational study. Moreover, [@B5] study has shown that the fasting glucose levels and 2-h glucose levels of oral glucose tolerance test were significantly higher in patients with gallstones than those without gallstones. As well known, hemoglobin A1c is an important measure of glycemic control. It has been a better indicator of long-term glycemic control. [@B1] study has shown that the prevalence of gallstones was higher among patients with high level of hemoglobin A1c. That is, high glycemic status is associated with a high prevalence of gallstones ([@B5]; [@B1]). Therefore, we make a rational explanation that patients with long-term use of metformin could have a good glycemic control, which further reduce the risk of gallstones development. The present study cannot prove this issue because hemoglobin A1c was not recorded due to the inherent limitation of the database. However, it indicates a further research direction on the association between gallstones and hemoglobin A1c levels.

Some limitations should be discussed. Theoretically, we need to test the association between gallstones and medications for comorbidities. It is difficult to conduct such a cohort study which needs to include all concomitant medications for adjustments. The rational step is to test the relative risk of gallstones associated with one potential drug. According to the recommendation of [@B2] metformin is the first-line medication for patients with type 2 diabetes mellitus. That is why we only included metformin for statistical analysis. However, it indicates a further research direction on the association between gallstones and other concomitant medications.

Some strength should be discussed. To the best of our knowledge, this is the first epidemiological study to explore the association between gallstones and metformin use. This is a unique finding supported by a large database.

Conclusion
==========

We conclude that long-term use of metformin is associated with reduced risk of gallstones. A further research is needed to clarify the association between gallstones and hemoglobin A1c levels.
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